Phase 3 Readout

OTLK: Phase 3 Topline: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impair

Name: Phase 3 Topline: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impair
Start: 2027-12-01
End: 2027-12-01

December 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2027
Company: Outlook Therapeutics, Inc. (OTLK)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impair

December 1, 2027

OTLK overview →

Company: Outlook Therapeutics, Inc. (OTLK)
Indication: Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration